[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645431":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Alder Hey Children's NHS Foundation Trust","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients on GLP1 receptor agonist",null,"Patients being treated with GLP1 receptor agonist in addition to lifestyle interventions",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients not on GLP1 receptor agonist","Patients not being treated with GLP1 receptor agonist and only on lifestyle intervention",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Anand Ramakrishnan, MD (Ped), MSc (Diab), PhD endo","CONTACT","+44 01512525956","senthil.senniappan@alderhey.nhs.uk",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Anand Ramakrishnan, MBBS, MD, MRCPCH, DipUKMP","07404613764","anand.ramakrishnan@alderhey.nsh.uk",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Alder Hey Children's hospital","RECRUITING","Liverpool","Merseyside","L122AP","United Kingdom","UK",{"type":35,"coordinates":36},"Point",[37,38],-2.97794,53.41058,{"lat":38,"lon":37},[41],{"name":22,"role":18,"phone":23,"phoneExt":10,"email":42},"anand.ramakrishnan@alderhey.nhs.uk",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645431","magnetic-resonance-imaging-assessment-of-multiorgan-health-in-obesity-100645431",false,"NCT07702825","Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity","Impact of Weight Loss Interventions on Multiorgan Health, Detected by Quantitative MRI, in Children and Young People With Severe Obesity.","FIT-YOUNG","Inclusion Criteria:\n\n* Age 12 to \\\u003C18 years at the time of enrolment\n* BMI \\>99.6th centile or \\>2.67 SDS\n* Informed consent from parent(s) (or person with parental responsibility) and assent from the child or young person for participants aged less than 16 years (or)\n* Informed consent from the participant if aged ≥ 16 years.\n\nExclusion Criteria:\n\n* Body weight above upper limit of the scanner (\\>250 kilograms)\n* Needs general anaesthesia for the MRI scanning\n* Any contraindications for MRI- Metal implants\u002Fclaustrophobia\n* Previous use of GLP-1 receptor agonist\n* Refusal to consent or refusal to assent from a competent older adolescent.","ALL","12 Years","18 Years",{"count":57,"type":58},30,"ESTIMATED","9 Months","OBSERVATIONAL","The goal of this study is to quantify the body composition and organ fat distribution changes with obesity interventions in adolescents with severe obesity. The main question the investigators aim to answer is if there is improvement in organ health with weight loss intervention. The investigators will be comparing the degree of these changes between children being treated with GLP1 receptor agonists in addition to lifestyle changes and those managed with lifestyle changes alone. Participants will undergo MRI body composition at baseline and after 9 months.",[63],"Childhood Obesity",[65,66,67],"Obesity","GLP1 receptor agonist","MRI Body composition","2026-07-13",{"date":70,"type":71},"2026-07-14","ACTUAL",{"date":73,"type":71},"2026-03-06",{"date":75,"type":58},"2028-01",{"name":5,"class":6},1]